Use of Proven Heart Failure Therapies Not Standardized in U.S.
September 23, 2008 - New analysis from the largest outpatient study of heart failure patients in the U.S. shows they are receiving inconsistent care, according to the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF), sponsored by Medtronic, Inc.
The results are being presented this week as posters at the 12th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Toronto. IMPROVE HF was designed to quantify and improve quality of care for heart failure patients by promoting the use of evidence-based, guideline-recommended therapies.
“These new data represent novel observations obtained in the outpatient environment and demonstrate that patients suffering from heart failure are not receiving consistent care in accordance with recommended evidence-based guidelines,” said Clyde Yancy, M.D., co-chair of the IMPROVE HF Scientific Steering Committee, and medical director at the Baylor Heart and Vascular Institute, Baylor University Medical Center in Dallas. “Previously we could only speculate on the quality of heart failure care in the outpatient arena. Now we know and there are reasons for concern.”
Specifically, the new data demonstrates several gaps in heart failure guideline adherence:
1. Use of device and drug therapy - Heart failure patients without implantable cardiac devices (implantable cardioverter-defibrillators) or cardiac resynchronization therapy-defibrillators (CRT-Ds) versus those with devices were less likely to receive the appropriate evidence-based therapies. Patients with ICD/CRT-D devices were significantly more likely than those without devices to receive ACE inhibitors (ACEI) /angiotensin-receptor blockers (ARB) (82.7 percent versus 78.6 percent) or beta blockers (BB) (90.6 percent versus 84.2 percent). Patients with CRT/CRT-D devices were significantly more likely to receive aldosterone antagonists (40.3 percent versus 34.1 percent) than patients without devices.
2. Impact of dedicated heart failure clinics on care - Clinics with two or more devoted heart failure nurses or physician’s assistants (PAs) were independently associated with improved quality of care in three of the seven quality measures that were assessed in the study. Notably, outpatient cardiology practices with at least two heart failure dedicated nurses/PAs were shown to be associated with increased adherence to ACEI/ARB and ICD/CRT-D interventions as well as the delivery of heart failure education. This evidence suggests a heart failure disease management program and/or a team model may positively influence the quality of care. However, the benefit was not demonstrated across all heart failure care measures reviewed in this study.
3. Variations in adjunct care - Gaps and variations among cardiology practices in documented care for certain guideline-recommended adjunctive therapies were revealed. Notably, on average, only 7.3 percent of eligible African-Americans received the recommended medications to lower blood pressure and relax veins and arteries.
“These results send a clear message that cardiology practices need to have systematic methods to employ the best evidence-based care for heart failure,” said Gregg C. Fonarow, M.D., co-chair of the IMPROVE HF Scientific Steering Committee and professor of medicine at the University of California at Los Angeles. “IMPROVE HF is an important study to document the need for more stringent practice patterns and to improve the care and outcomes for heart failure patients.”
An earlier analysis of IMPROVE HF baseline data demonstrated inconsistencies in care and underutilization of lifesaving device therapies for heart failure patients. Specifically, only 39 percent of eligible patients received a CRT device and only 51 percent who were eligible received ICD therapy.
About IMPROVE HF
IMPROVE HF is the first of its kind, large-scale, prospective study involving approximately 40,000 heart failure patients from approximately 160 cardiology practices in the United States. This new release of baseline data includes 15,381 patients and 167 clinics. The study is assessing seven performance measures including four on drug therapy, three on device therapy and heart failure education.
Chart reviews were conducted at baseline, and then again at six, 12, 18 and 24 months as part of the ongoing study and performance improvement initiative. All study data is being collected and analyzed by an independent clinical research organization.
Findings from IMPROVE HF were recently published in the July issue of Circulation, titled
“Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings from IMPROVE HF,”
For more information: www.medtronic.com
More like this
- Heart Failure Study Shows Improved Adherence To Care Guidelines
- Evidence-Based Heart Failure Treatments Vary Significantly
- Medtronic Seeks to Expand Indication for Heart Failure Device Therapy
- MedSolutions Offers New Program to Reduce Unnecessary ICD Surgeries
- Gaps in Treatments, Guidelines for Chronic Heart Failure